NEWARK, Del., Oct. 22, 2012 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that the U.S. Patent Office has allowed patent application 12/668,258 entitled "Yersinia Pestis Antigens, Vaccine Compositions and Related Methods." The claims cover plague antigens comprising Yersinia pestis F1 protein fused to the Company's thermostable iBioModulator protein, as well as vaccine compositions and a method for producing a protective immune response to the antigen. The invention was developed by scientists at the Fraunhofer USA Center for Molecular Biotechnology, iBio's research collaborator.
Plague is a disease caused by the bacterium Yersinia pestis and primarily infects animals, but can spread to humans through bites from infected fleas or contact with infected animals. It is also considered a potential bioterrorism weapon, and therefore a priority for effective vaccine development.
There is no plague vaccine currently approved for use in the U.S. Although killed whole-cell plague vaccines have been reported to protect against bubonic plague in animal models, they were not effective against pneumonic plague. By contrast, data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator protein, and produced via the iBioLaunch platform in green plants, provided complete protection of non-human primates against pneumonic plague.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch and iBioModulator platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.
The iBioModulator platform is separate from, but complementary to, the iBioLaunch platform and enables significantly improved vaccine products with higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production and is protected by both issued and pending patents. Further information is available at: www.ibioinc.com.
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
Robert Erwin, President
Douglas Beck, Chief Financial Officer
SOURCE iBio, Inc.